Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
Endometrial clear cell carcinoma
Mismatch repair protein status
Ovarian clear cell carcinoma
PD-L1
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Dec 2022
29 Dec 2022
Historique:
received:
19
06
2022
accepted:
22
12
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
3
1
2023
Statut:
epublish
Résumé
Clear cell carcinoma is an uncommon histologic subtype of ovarian and endometrial carcinoma with poor response to Platinium-based chemotherapy agents at high stages. Blockage of Programmed cell Death Ligand-1 (PD-L1), can be used in targeted immunotherapy. This study investigated Mismatch Repair Deficiency (MMR-D) status, PD-L1 expression, and the correlation between PD-L1 expression and microsatellite instability (MSI) status in ovarian and endometrial clear cell carcinomas. Ovarian clear cell carcinoma (OCCC) (n = 28) and endometrial clear cell carcinoma (ECCC) (n = 28) samples were evaluated for PD-L1 (in tumoral and peri-tumoral inflammatory cells), MSH6 and PMS2 expression by immunohistochemistry (IHC) study. PD-L1 expression > 1% in tumor cells and > 5% in peritumoral inflammatory cells were considered positive. The prevalence of PD-L1 expression was higher in ECCC (20/28, 71.43%) compared to OCCC tumor cells (16/28, 57.15%) (p > 0.05), while expression in peritumoral inflammatory cells was significantly higher in ECCC (25/28, 89.29%) compared to OCCC (11/28, 39.28%) (p < 0.05). MMR-D was observed in 5 cases, four OCCCs and one ECCC, among which, four (80%) showed PD-L1 expression in peritumoral inflammatory and tumor cells. The only OCCC case with extensive PD-L1 expression in tumor cells (> 50%) exhibited MSH6/MSH2 loss. No significant correlation was noted between PD-L1 expression and the pathologic stage or survival. PD-L1 expression was significantly associated with clear cell morphology, especially in the endometrium, independent of MMR protein status.
Sections du résumé
BACKGROUND
BACKGROUND
Clear cell carcinoma is an uncommon histologic subtype of ovarian and endometrial carcinoma with poor response to Platinium-based chemotherapy agents at high stages. Blockage of Programmed cell Death Ligand-1 (PD-L1), can be used in targeted immunotherapy. This study investigated Mismatch Repair Deficiency (MMR-D) status, PD-L1 expression, and the correlation between PD-L1 expression and microsatellite instability (MSI) status in ovarian and endometrial clear cell carcinomas.
METHODS
METHODS
Ovarian clear cell carcinoma (OCCC) (n = 28) and endometrial clear cell carcinoma (ECCC) (n = 28) samples were evaluated for PD-L1 (in tumoral and peri-tumoral inflammatory cells), MSH6 and PMS2 expression by immunohistochemistry (IHC) study. PD-L1 expression > 1% in tumor cells and > 5% in peritumoral inflammatory cells were considered positive.
RESULTS
RESULTS
The prevalence of PD-L1 expression was higher in ECCC (20/28, 71.43%) compared to OCCC tumor cells (16/28, 57.15%) (p > 0.05), while expression in peritumoral inflammatory cells was significantly higher in ECCC (25/28, 89.29%) compared to OCCC (11/28, 39.28%) (p < 0.05). MMR-D was observed in 5 cases, four OCCCs and one ECCC, among which, four (80%) showed PD-L1 expression in peritumoral inflammatory and tumor cells. The only OCCC case with extensive PD-L1 expression in tumor cells (> 50%) exhibited MSH6/MSH2 loss. No significant correlation was noted between PD-L1 expression and the pathologic stage or survival.
CONCLUSION
CONCLUSIONS
PD-L1 expression was significantly associated with clear cell morphology, especially in the endometrium, independent of MMR protein status.
Identifiants
pubmed: 36581850
doi: 10.1186/s12885-022-10478-7
pii: 10.1186/s12885-022-10478-7
pmc: PMC9801577
doi:
Substances chimiques
B7-H1 Antigen
0
DNA-Binding Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1362Informations de copyright
© 2022. The Author(s).
Références
Int J Gynecol Cancer. 2021 Apr;31(4):605-616
pubmed: 32948640
Front Oncol. 2021 Oct 19;11:666815
pubmed: 34737943
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Gynecol Oncol. 2018 Jan;148(1):213-221
pubmed: 29174566
Gynecol Oncol. 2014 Oct;135(1):81-4
pubmed: 25093288
Am J Surg Pathol. 2017 Mar;41(3):326-333
pubmed: 27984238
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Mod Pathol. 2017 Nov;30(11):1622-1632
pubmed: 28752845
Front Oncol. 2021 Dec 02;11:732782
pubmed: 34926250
Arch Gynecol Obstet. 2022 Dec;306(6):2133-2142
pubmed: 35507079
Int J Clin Oncol. 2016 Jun;21(3):448-55
pubmed: 26864303
Oncoimmunology. 2017 Jan 6;6(2):e1277308
pubmed: 28344892
J Gynecol Oncol. 2016 May;27(3):e31
pubmed: 27029752
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Gynecol Oncol. 2018 Nov;151(2):381-389
pubmed: 30217369
Ann Oncol. 2016 Apr;27 Suppl 1:i50-i52
pubmed: 27141072
J Gynecol Oncol. 2017 Nov;28(6):e77
pubmed: 29027395
Int J Surg Pathol. 2020 Feb;28(1):31-37
pubmed: 31311367
Anticancer Res. 2010 Apr;30(4):1327-34
pubmed: 20530448
Gynecol Oncol. 2012 Sep;126(3):481-90
pubmed: 22525820
Virchows Arch. 2020 Dec;477(6):845-856
pubmed: 32594230
J Ovarian Res. 2019 Apr 30;12(1):37
pubmed: 31039792
Gynecol Oncol. 2019 Dec;155(3):483-488
pubmed: 31653509
J Ovarian Res. 2021 May 4;14(1):63
pubmed: 33941230
Int J Gynecol Pathol. 2021 Nov 1;40(6):575-586
pubmed: 33332859